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This introductory chapter aims at presenting an overview of delirium 
in palliative care. In this setting, it is one of the most frequent, but often 
misunderstood and difficult to treat, symptoms. Moreover, this is a matter of 
paramount importance as delirium is associated with a heightened rate of falls, 
increased cognitive and functional damage, and important patient and family 
psychological discomfort. In these particularly vulnerable patients, distress — 
expressed as a feeling of fear, anguish, humiliation — can be deleterious and is 
ethically unacceptable. Delirium is further associated with increased healthcare 
costs [1].
The term delirium derives from the Latin word deliria which literally means “to 
come out of the trace”. It refers to a serious change in the mental state that leads to 
confusion and reduced awareness of the environment. This change is often accom-
panied by perceptual symptoms, such as hallucinations, or by cognitive symptoms 
such as disorientation and memory loss [2]. Nevertheless, rather than a symptom, 
delirium is a complex neurocognitive syndrome characterized by brain dysfunc-
tion with perturbations in the degree of consciousness, attention, thinking, 
perception, memory, psychomotor behavior, emotional sphere, and sleep–wake 
rhythm [3]. These clinical features differentiate delirium from a state of agitation 
that can be due to other undetected symptoms or physical needs (e.g., pain or full 
bladder).
2. The extent of the problem
In the palliative care setting, delirium represents a frequent clinical condition. 
In patients with advanced cancer, for instance, research showed that its preva-
lence varies from 13 to 88% [4]. Despite on admission delirium prevalence ranges 
between 13 to 42%, the higher prevalence occurs in the last 24 to 48 hours of life 
(terminal delirium), when the phenomenon becomes part of the complex picture 
of multiorgan dysfunction [5]; in this context, delirium is particularly difficult 
to treat, and it is considered as the predominant symptom for starting terminal 
sedation [1]. Overall, the reversibility is about 30% [6] and failure to respond to 
treatment may become indicative of a worse prognosis already after the first week 
of palliative care [7].
Despite its high prevalence and clinical significance, delirium is poorly sought; 
of note, Rainsford et al. [8] demonstrated that the diagnosis of delirium was 
performed only in 30% of in-hospice patients.
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3. Mechanism and causes
The genesis of delirium is multifactorial. In general, all conditions that can 
induce a neuroinflammatory process are potential causes of delirium. Through the 
action of cytokines, chemokines, tumor necrosis factor-alpha, and other inflamma-
tory agents (e.g., interleukin (IL)-1, and IL-6), a cascade of events is activated; it 
culminates in endothelial and microvascular damage and alterations of the blood–
brain barrier. Again, disorders of neurotransmitter pathways such as the dopamine 
and acetylcholine systems, involving respectively dopamine excess or acetylcholine 
depletion, have a key role in the pathophysiology of delirium [9]. Further, in 
clinically ill patients, the impairment of cerebral oxidative metabolism is another 
potential mechanism to be considered [10].
Although drugs such as opioids, anticholinergic drugs, steroids, chemotherapies 
and metabolic disorders such as metabolic encephalopathy, nutritional deficien-
cies, electrolyte disturbances, dehydration are the main inducers of delirium, many 
conditions can provoke delirium. These causes include constipation, infections, 
hematological changes, paraneoplastic syndromes, brain neoplasms, central ner-
vous system (CNS) secondarisms, seizure disorders, hypoxia, hypo/hypercarbia, 
and environmental factors. Several acronyms are commonly used to memorize and 
recognize potential causes. Sometimes the cause of the delirium cannot be found 
(Table 1).





























Adapted from Bush [3].
Table 1. 
Acronyms used to memorize possible causes of delirium in palliative care.
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4. Clinical features
According to the type of psychomotor activity, there are three subtypes of 
delirium:
• Hyperkinetic form. It features agitation, restlessness, with or without 
hallucinations.
• Hypokinetic form. It is improperly referred to as “quiet delirium” or “acute 
encephalopathy”. This type is featured by apathy, declined responsiveness, 
reduced psychomotor function, withdrawn attitude, lethargy, and drowsiness.
• Mixed form. The person may exhibit a fluctuation between the hypoactive and 
hyperactive subtypes where there is an alternation between the hypokinetic 
form and the hyperkinetic form.
In palliative care, the hypoactive and mixed are the most frequent subtypes of 
delirium. The lack of tangible agitation and the erroneous belief that the patient 
is drowsy because of illness, drugs administered, or an underlying depressed 
habitus, make this subtype very often misunderstood. This is a serious care gap 
as hypoactive delirium is frequently associated with perceptual disturbances and 
distress [11].
5. Diagnosis
According to the recently updated guidelines of the National Institute for Health 
and Clinical Excellence (NICE), the assessment of delirium should be performed 
in all hospitalized patients who are at risk of experiencing it, including oncological 
and terminally ill patients (respectively up to 88% and 50% incidence) [12]. Despite 
this and other recommendations, the lack of a systematic assessment for delirium is 
a serious issue.
The Diagnostic and Statistical Manual of Mental Disorders (DSM-V, 2013) [2] 
defined delirium based on four criteria, namely:
• An alteration of consciousness characterized by a reduced ability to focus, 
maintain or shift attention.
• A cognitive change (such as memory deficit), language alteration, and the 
development of a perceptual disorder (such as delusion) that are not depen-
dent on a pre-existing condition of dementia.
• A development of the disorder in a short time with daily fluctuations.
• Evidence collected from the medical history, physical examination and labora-
tory investigations that show that the disorder is caused by physical conditions 
resulting from a serious pathology, problems of alcohol abuse or drug intoxica-
tion, or withdrawal.
Of note, despite DSM-V is the gold standard for the diagnosis of delirium, it 
cannot be easily administered by non-psychiatrist personnel including nurses. This 
is a great limitation as nurses have constant contact with the patient throughout the 
day, and they could efficiently evaluate modifications in the patient’s attention and 
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awareness over time. Furthermore, diagnostic instruments for delirium are mostly 
based on the DSM-III or IV. Thus, many efforts are being made to validate updated 
versions or to develop new tools [13].
In addition to the DSM-V, the International Classification of Diseases (ICD) clas-
sification from the World Health Organization (WHO) is conventionally adopted. 
The 11th Revision (ICD-11) defined delirium as a neurocognitive disorder charac-
terized by ‘disturbed attention (i.e., reduced ability to direct, focus, sustain, and shift 
attention) and awareness (i.e., reduced orientation to the environment) that develops 
over a short period of time and tends to fluctuate during the course of a day, accompa-
nied by other cognitive impairment such as memory deficit, disorientation, or impair-
ment in language, visuospatial ability, or perception. Disturbance of the sleep-wake cycle 
(reduced arousal of acute onset or total sleep loss with reversal of the sleep-wake cycle) 
may also be present. The symptoms are attributable to a disorder or disease not classified 
under mental and behavioural disorders or to substance intoxication or withdrawal or 
to a medication’ [14]. Thus, this approach includes more details on non-cognitive 
features, and it seems to better address the problem of the diagnostic and patho-
physiological difference between delirium and states of dementia.
Practically, suspicion of delirium can be induced by changes or fluctuations in 
usual behaviors. These fluctuations can occur in the day’s course, although more 
severe symptoms usually manifest during the evening and the night. The diagnosis 
of delirium requires healthcare professionals who are trained and competent in 
the diagnosis of delirium. It can be made by referring to tools or simple cognitive 
tests, for example by having the patient recite the days of the week or the months 
of the year. Among the most commonly used instruments, there are the Confusion 
Assessment Method (CAM) [15] and the Delirium Observation Screening (DOS) 
scale [16]. Although the choice of tool to be used depends on the level of training of 
the staff, commonly used tests may require a short training period. About CAM, the 
training manual is available at the website of the American Geriatrics Society [17]. 
On the contrary, the DOS can be administered without specific training.
The CAM method was also validated in palliative care [18]. It consists of a 9-item 
questionnaire and a diagnostic algorithm encompassing four items/features. In 
particular, the features “acute onset and fluctuating course” and “inattention” are 
needed, along with “disorganized thinking” or “altered level of consciousness” [3]. 
The DOS scale is a 13-item tool. Since each item can be scored 0 or 1, the total score 
can range from 0 to 13 and a score of ≥3 indicates delirium. Similar to CAM, it was 
validated in palliative care patients [19].
Among the other tools, there is the 5-item Nursing Delirium Screening Scale 
(Nu-DESC) [20]. As Bush et al. [21] highlighted, it offers poor sensitivity for 
detection of the hypoactive form and is not validated in palliative care. Other tools 
are the NEECHAM Confusion Scale [22], the 13-item Delirium Rating Scale (DRS) 
[23] and the Memorial Delirium Assessment Scale (MDAS). This latter was also 
validated in palliative care [24].
6. Prevention
Prevention is based on early recognition of any precipitating causes. 
Pharmacological interventions, including antipsychotics, are not recommended 
as prophylactic strategies. For this purpose, the NICE guidelines recommend only 
non-pharmacological interventions [12]. Avoiding polypharmacy, in particular 
delirogenic drugs such as benzodiazepines, opioids, and corticosteroids is of 
paramount importance for delirium prevention. Moreover, in all frail patients, and 
even more in the presence of risk factors for delirium, multi-component preventive 
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interventions must be implemented. These approaches are based on temporal–spa-
tial reorientation, mobilization programs, sleep hygiene, maintenance of adequate 
hydration, and provision of visual and hearing aids, if used by the patient.
7. Therapy
Treatment of delirium often requires the combination of pharmacological (e.g. 
major tranquilizers) and non-pharmacological (reorientation, communication, and 
sleep hygiene) interventions tailored to the patient.
7.1 Causal therapy
Clinical and physical assessment including appropriate laboratory and radio-
logical investigations can help identify the cause of the delirium. Moreover, rapid 
recognition and treatment of the underlying cause can often avoid resorting to 
more complex symptomatic pharmacological and non-pharmacological strategies. 
Treatment of the underlying cause may include:
• Correction of potential fluid or electrolyte disturbances
• Removal of potential pharmacological agents
• Removal of potential physical issues
• Adequate pain assessment (also looking for non-verbal signs in cognitively 
impaired individuals) and management [25]
For evaluating the delirogenic potential of drugs, optimizing the medication 
use, the DEL-FINE score can be used. Drugs (and drug withdrawal) are assigned a 
score ranging from “three = strong delirogenic potential” to “zero = no delirogenic 
potential”. For instance, a score of three is assigned to amitriptyline, atropine, 
clomipramine, and the withdrawal of benzodiazepines, ethanol, and opioids [26].
Nevertheless, the causal treatments can often be difficult as, even when the root 
cause is identified, it cannot be reversible. Therefore, symptomatic treatments are 
often used. These treatments include pharmacological therapy and non-pharmaco-
logical strategies.
7.2 Symptomatic treatment
Drugs useful for managing delirium may include antipsychotics and in selected 
cases benzodiazepines including diazepam, lorazepam, and midazolam. The 
latter class of drug can be indicated in the case of alcohol withdrawal or epilepsy 
delirium. Other drugs such as α-2 receptor agonists, psychostimulants, cholinester-
ase inhibitors, and melatonergic drugs are also used although no recommendations 
have been released so far.
About antipsychotics, it was demonstrated that both conventional (e.g., halo-
peridol) and atypical antipsychotics including olanzapine, risperidone, quetiapine, 
aripiprazole are effective in the treatment of delirium. Of note, the efficacy and 
safety of haloperidol at low doses (up to 10 mg/day) are comparable to those of 
atypical antipsychotics such as risperidone, olanzapine, and quetiapine [27].
In palliative care, haloperidol is one of the most used drugs. It is commonly 
administrated for the treatment of delirium and for the prevention and/or 
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treatment of nausea/vomiting (including the opioid-induced ones) [28]. Even if 
it represents the preferred drug in the treatment of delirium, its use is limited by 
concern for side effects. Usually, the onset of extrapyramidal disorders is dose-
dependent and cardiotoxicity — QTc prolongation or torsades de pointes (with 
a QTc > 450–500 ms immediate drug withdrawal is recommended) — generally 
rarely occurs for low doses [29]. However, in patients under palliative care, many 
factors such as the severity of the underlying disease and organ damage, comorbidi-
ties, cachexia, hypoproteinemia, advanced age, and polytherapy can increase the 
risk of side effects. For example, haloperidol pharmacokinetics (Table 2) mostly 
depends on CYP2D6 functioning.
About doses, in mild delirium with no underlying psychiatric illness haloperidol 
can be used at the dose of 0.5–1 mg bid, both oral or subcutaneous (0.25–0.5 mg 
for elderly patients). In moderate delirium, the dose can be doubled. In severe and 
terminal delirium the dose is 0.5–4 mg both oral or subcutaneous (possibly repeated 
every 45–60 min) with a maximum of 2–20 mg/day.
Among the other antipsychotics, risperidone (0.5–4 mg/day) could be use-
ful in patients requiring high doses of haloperidol or at high risk of developing 
haloperidol-induced extrapyramidal or cardiac effects. Olanzapine (2.5–10 mg/day, 
orally or i.m.) has an efficacy comparable to haloperidol but can induce sedation 
due to its antihistaminergic action; thus, it is not recommended in elderly patients 
with dementia or hypoactive delirium, although its use can be beneficial for the 
regulation of the sleep–wake rhythm [30]. Quetiapine (from 12.5–25 mg/day up to 
an average dose of 50–175 mg/day) has an intense antihistaminergic activity which 
can worsen confusion. It can also cause hypotension. Finally, the first-generation 
antipsychotic agent levomepromazine is also used to address intractable nausea 
or vomiting, and for severe delirium in the last days of life. This phenothiazine is 
administered orally or by subcutaneous bolus injection (10–25 mg, repeatable as 
required after 2 hours) or continuous subcutaneous infusion (25–100 mg/day).
It must be emphasized that the efficacy of antipsychotics and other pharmacolog-
ical interventions for the treatment of delirium in palliative care is still under debate 
[31, 32]. The use of antipsychotics and/or other medications becomes inevitable for 
the management of hyperactive or mixed delirium with severe agitation and anxiety 
but they must be given short-term and at the lowest effective dose. Symptomatic 
therapy of delirium is also mandatory if it becomes a source of suffering.
T1/2 p.o.: after a single dose (e.g., 2–4 mg) 14.5–36.7 hrs; up to 21 days after chronic 
administration
i.v.: 10.1–26.2 hrs
i.m.: 20.7 hrs (decanoate i.m.: 21 days)
Onset of action p.o.: > 1 hr.
s.c.:10–15 min
i.v.: seconds





Abbreviations: p.o., oral; i.m., intramuscular; s.c., subcutaneous; i.v., intravenous; Vd: Volume of distribution; PPB, 
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7.3 Non-pharmacological strategies
Non-pharmacological approaches such as behavioral and educational inter-
ventions, and cognitive activities as well as methods aimed at improving sleep, 
vision, and hearing functioning, are useful for addressing the issue of delirium. 
Encouraging family visits is another effective non-pharmacological strategy to be 
strengthened.
Communication strategies play a role of fundamental importance. Among the 
many examples reported, those proposed by the Mother Élisabeth Bruyère health 
care organization seem to be simple and effective. According to these suggestions, 
it is mandatory to use a calming voice, speak slowly and in short simple sentences, 
present one idea at a time and if needed, repeat the sentence. It is also suggested to 
avoid contradicting the person, accepting his/her arguments. Finally, rapid move-
ments or gestures that can be misinterpreted as aggressive must be avoided [33].
8. Conclusion
Although clinical experience and scientific evidence underline that delirium can 
lead to multiple clinical and healthcare problems and that its timely recognition 
and treatment can induce a remission of the clinical picture, screening of cognitive 
conditions and delirium remains an unmet need. As the efficacy of pharmacological 
treatments has not yet been proven, greater efforts must be focused on prevention 
and early diagnosis. In short, the strategies to be adopted for prevention are quite 
codified. It is crucial to recognize potential risk factors and, since according to the 
ICD-11, delirium is essentially featured by disturbed attention and awareness, a 
careful evaluation of changes in usual behaviors is mandatory. The suspicion, in 
turn, must direct towards the administration of validated tools. Although the effec-
tiveness of antipsychotics and other pharmacological treatments is still questioned, 
the use of these drugs is especially necessary for the treatment of hyperactive or 
mixed delirium featuring severe agitation and self or hetero-injurious behaviors. 
The hypoactive subtype, although very frequent, is little recognized and requires 
multicomponent non-pharmacological approaches.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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